Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | Both sides next revision |
paxlovid [2022/08/27 12:48]
mathew | paxlovid [2022/08/27 12:52] (current)
mathew |
|---|
| |
| ==== Press Releases ==== | ==== Press Releases ==== |
| On Friday, November 5, 2021, Pfizer issued a stunningly optimistic press release for a new drug, stating a risk reduction of 89% for hospitalization and death from COVID-19.((November 5, 2021 | Pfizer | [[https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate|Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study]])) | On Friday, November 5, 2021, Pfizer issued a stunningly optimistic press release for a new drug, stating "overwhelming efficacy" and a risk reduction of 89% for hospitalization and death from COVID-19.((November 5, 2021 | Pfizer | [[https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate|Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study]])) The press release claimed that after 28 days there were 0 deaths in the treatment arm and 10 in the placebo arm, with 41 vs. 6 hospitalizations. |
| |
| |
